Therapy Areas: Devices
Vitrolife's EmbryoScope+ receives sales approved in US
14 May 2018 -

Medical device company Vitrolife AB (STO:VITR) announced on Friday the receipt of market approval for the time-lapse incubator EmbryoScope+ in the US, considered the world's third largest market measured in terms of number of IVF treatments.

EmbryoScope+ is a time-lapse system with an integrated incubator with a capacity for 15 patients. Vitrolife is a market leader of time-lapse systems for use in assisted reproduction for undisturbed culture and improved selection of embryos.

With this approval, Vitrolife will be able to offer EmbryoScope+ to clinics in US.

Vitrolife develops, produces and markets medical devices for assisted reproduction.

Login
Username:

Password: